Abstract
The clinical use of nitisinone, also known as NTBC, has a fascinating history in the context of modern medical practice. This is a remarkable account of how a weed killer has become the mainstay in the treatment of hereditary tyrosinaemia type 1, a lethal inherited metabolic disorder. The story is still unfolding as nitisinone is now being developed for alkaptonuria.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Anikster, Y., Nyhan, W.L., Gahl, W.A.: NTBC and alkaptonuria. Am. J. Hum. Genet. 63, 920–921 (1998)
Holme, E., Lindstedt, S.: Treatment of tyrosinemia type 1 with an enzyme inhibitor (NTBC). Int. J. Pediatr. 10(1), 41–43 (1995a)
Holme, E., Lindstedt, S.: Diagnosis and management of tyrosinemia type 1. Curr. Opin. Pediatr. 7, 726–732 (1995b)
Holme, E., Lindstedt, S.: Tyrosinaemia type I and NTBC (2-(2-nitro-4- trifluoromethylbenzoyl)-l, 3-cyclohexanedione). J. Inherit. Metab. Dis. 21, 507–517 (1998)
Holme, E., Lindstedt, S.: Nontransplant treatment of tyrosinemia. Clin. Liver Dis. 4, 805–814 (2000)
Kobrinsky, N., Slojander, D.: Response of metastatic recurrent neuroblastoma to nitisinone: a modulator of tyrosine metabolism. Pediatr. Blood Cancer 46, 517–520 (2006)
Lindblad, B., Lindstedt, S., Steen, G.: On the enzymatic defects in hereditary tyrosinemia. Proc. Natl. Acad. Sci. U.S.A. 74, 4641–4645 (1977)
Lindstedt, S., Holme, E., Lock, E.A., Hjalmarson, O., Strandvik, B.: Treatment of hereditary tyrosinemia type 1 by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340, 813–817 (1992)
Lock, E.A., Ellis, M.K., Gaskin, P., Robinson, M., Auton, T.R., Provan, W.M., Smith, L.L., Prisbylla, M.P., Mutter, L.C., Lee, D.L.: From toxicological problems to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluromethylbenzoyl)- 1,3 cyclohexanedione (NTBC), its toxicology and development as a drug. J. Inherit. Metab. Dis. 21, 498–506 (1998)
Manga, P., Orlow, S.J.: Informed reasoning: repositioning of nitisinone to treat oculocutaneous albinism. J. Clin. Invest. 121, 3828–3831 (2011)
Onojafe, I.F., Adams, D.R., Simeonov, D.R., Zhang, J., Chan, C.C., Bernardini, I.M., Sergeev, Y.V., Dolinska, M.B., Alur, R.P., Brilliant, M.H., Gahl, W.A., Brooks, B.P.: Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism. J. Clin. Invest. 121, 3914–3923 (2011)
Orfadin EPAR.: Available from: www.ema.europa.eu/ (2009). 20 Jan 2013
Santra, S., Baumann, U.: Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin. Pharmacother. 9, 1229–1236 (2008)
Suzuki, Y., Oda, K., Yoshikawa, Y., Maeda, Y., Suzuki, T.: A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria. J. Hum. Genet. 44, 79–84 (1999)
Tyrosinemia Type.: Available from: http://www.omim.org/entry/276700?search=tyrosinemia%20type%2018chighlight=1%20tyrosinemia%20type (2012). 27 Jan 2013
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Kamlesh, S. (2015). History of Nitisinone (NTBC). In: Rovenský, J., Urbánek, T., Oľga, B., Gallagher, J. (eds) Alkaptonuria and Ochronosis. Springer, Cham. https://doi.org/10.1007/978-3-319-15108-3_26
Download citation
DOI: https://doi.org/10.1007/978-3-319-15108-3_26
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-15107-6
Online ISBN: 978-3-319-15108-3
eBook Packages: MedicineMedicine (R0)